x New Patents Iron proteinaceous derivatives, obtained from ferric or ferrous salts and lysozyme with glutaric or 1,2-cyclohexanedicarboxylic anhydride and their pharmaceutical use in the oral treatment of iron-deficiency anemia, are described. 4939128 ESTER OF ASCORBIC ACID 2-PHOSPHATE AND PHARMACEUTICAL USE ment of diseases associated with impairment calcium metabolism. The compounds are q tained for example by converting, in acc pound of formula See Patent for Cheml Structure (II) wherein X1 is a function~ modified phosphono group and X2 is a free functionally modified phosphono group, and, if appropriate X2, into the free phosphc group. 4939133 Kaneyoshi Kato, Norio Shimamoto, Osaka, Japan assigned to Takeda Chemical Industries Ltd The present invention relates to a compound of the formula: See Patent for Chemical Structure wherein R1 is a hydrogen atom, carboxylic acid acyl or carbamoyl which may be substituted; R is an aliphatic hydrocarbon group which may be substituted or alicylic hydrocarbon group which may be substituted, or a salt thereof. The compound of the present invention has the effects to prevent and improve dysfunctions caused by ox- ygen free radicals, and can be used as preventive and therapeutic drugs against dysfunctions in the circulatory system. 4939130 SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS AND PHARMACEUTICAL USE N-SUBSTITUTED 2-HYDROXY- ALPHA-OXO BENZENEACETAMIDES AND PHARMACEUTICAL COMPOSITIONS HAVING ACTIVITY AS MODULATORS O THE ARACHIDONIC ACID CASCADE David T Connor, Daniel L Flynn, Wiaczesl Cetenko, Jagadish C Sircar, Charles Schwend Elizabeth Johnson, Roderick Sorenson, Paul Unangst assigned to Warner-Lambert Comp~ The present invention relates to novel substituted 2-hydroxybenzamide and substituted 2-hydroxy- alpha-oxo-benez~ acetamide compounds pharmaceutical compc tions, and methods of use for therefore for~ treatment of diseases in which products havi lipoxygenase enzyme activity contribute to pathological condition. Selected novel int mediates are also the present invention. Knut A Jaeggi, Le Widler, Basel, Switzerland assigned to Ciba-Geigy Corporation 4939135 Alkanediphosphonic acids, in particular hetero- arylalkanediphosphonic acids of formula See Patent for Chemical Structure (I) wherein R 1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N- substituted at a N-atom which is capable of sub- stitution by lower alkyl, lower alkoxy and/or halogen, and R2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treat- PHARMACEUTICAL COMPOSITIONS AND METHOE OF TREATMENT TO PREVEN'I AND TREAT CORNEAL SCAR FORMATION PRODUCED BY LASER IRRADIATION Stella Robertson, Herman Kunkle, Michael Stern assigned to Alcon Laboratories Inc Methods for preventing and treating corn haze resulting from exposure of the eye to la irradiation are disclosed. The methods inch administration of compositions of wow healing modulators to the eye. Compositions use in preventing and treating the corneal h~ are also disclosed.

4939133 N-substituted 2-hydroxy-alpha-oxo benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade

Download PDF Report

Upload
nguyenque
View
212
Download
0

Embed Size (px)

Citation preview

Page 1: 4939133 N-substituted 2-hydroxy-alpha-oxo benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade

x N e w P a t e n t s

Iron proteinaceous derivatives, obtained from ferric or ferrous salts and lysozyme with glutaric or 1,2-cyclohexanedicarboxylic anhydride and their pharmaceutical use in the oral treatment of iron-deficiency anemia, are described.

4939128

ESTER OF ASCORBIC ACID 2-PHOSPHATE AND

PHARMACEUTICAL USE

ment of diseases associated with impairment calcium metabolism. The compounds are q tained for example by converting, in a c c pound of formula See Patent for Cheml Structure (II) wherein X1 is a function~ modified phosphono group and X2 is a free functionally modified phosphono g r o u p , and, if appropriate X2, into the free phosphc group.

4939133

Kaneyoshi Kato, Norio Shimamoto, Osaka, Japan assigned to Takeda Chemical Industries Ltd

The present invention relates to a compound of the formula: See Patent for Chemical Structure wherein R1 is a hydrogen atom, carboxylic acid acyl or carbamoyl which may be substituted; R is an aliphatic hydrocarbon group which may be substituted or alicylic hydrocarbon group which may be substituted, or a salt thereof. The compound of the present invention has the effects to prevent and improve dysfunctions caused by ox- ygen free radicals, and can be used as preventive and therapeutic drugs against dysfunctions in the circulatory system.

4939130

SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS

AND PHARMACEUTICAL USE

N-SUBSTITUTED 2-HYDROXY- ALPHA-OXO

BENZENEACETAMIDES AND PHARMACEUTICAL

COMPOSITIONS HAVING ACTIVITY AS MODULATORS O

THE ARACHIDONIC ACID CASCADE

David T Connor, Daniel L Flynn, Wiaczesl Cetenko, Jagadish C Sircar, Charles Schwend Elizabeth Johnson, Roderick Sorenson, Paul Unangst assigned to Warner-Lambert Comp~ The present invention relates to novel substituted 2-hydroxybenzamide and substituted 2-hydroxy- alpha-oxo-benez~ acetamide compounds pharmaceutical compc tions, and methods of use for therefore for~ treatment of diseases in which products havi lipoxygenase enzyme activity contribute to pathological condition. Selected novel int mediates are also the present invention.

Knut A Jaeggi, Le Widler, Basel, Switzerland assigned to Ciba-Geigy Corporation 4939135

Alkanediphosphonic acids, in particular hetero- arylalkanediphosphonic acids of formula See Patent for Chemical Structure (I) wherein R 1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N- substituted at a N-atom which is capable of sub- stitution by lower alkyl, lower alkoxy and/or halogen, and R2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treat-

PHARMACEUTICAL COMPOSITIONS AND METHOE

OF TREATMENT TO PREVEN'I AND TREAT CORNEAL SCAR FORMATION PRODUCED BY

LASER IRRADIATION

Stella Robertson, Herman Kunkle, Michael Stern assigned to Alcon Laboratories Inc

Methods for preventing and treating corn haze resulting from exposure of the eye to la irradiation are disclosed. The methods inch administration of compositions of wow healing modulators to the eye. Compositions use in preventing and treating the corneal h~ are also disclosed.